4-氨甲基-1(2H)-酞嗪酮 | 22370-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-氨甲基-1(2H)-酞嗪酮
• 中文别名: 4-(氨基甲基)-1(2H)-二氮杂萘酮
• 英文名称: 4-(aminomethyl)- phthalazin-1(2H)-one
• 英文别名: 4-aminomethyl-2H-phthalazin-1-one；4-Aminomethyl-2H-phthalazin-1-on；4-(aminomethyl)phthalazin-1(2H)-one；1-Aminomethyl-phthalazin-(4)；4-Aminomethyl-1-phthalazon；4-(Aminomethyl)-1(2H)-phthalazinone；4-(aminomethyl)-2H-phthalazin-1-one
• CAS: 22370-18-9
• 化学式: C₉H₉N₃O
• mdl: MFCD00462445
• 分子量: 175.19
• InChiKey: BCORFYODLSYUNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-氨甲基-1(2H)-酞嗪酮 、 2-(4-氧-3,4-二氢邻苯二甲秦)乙酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 49.0h， 以26%的产率得到2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)-N-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)acetamide
  参考文献：
  名称：

  Discovery of thiazolyl-phthalazinone acetamides as potent glucose uptake activators via high-throughput screening

  摘要：

  With the aim to discover orally active small molecules that stimulate glucose uptake, high throughput screening of a library of 5000 drug-like compounds was conducted in differentiated skeletal muscle cells in presence of insulin. N-Substituted phthalazinone acetamide was identified as a potential glucose uptake modulator. Several novel derivatives were synthesized to establish structure activity relationships. Identified lead thiazolyl-phthalazinone acetamide (7114863) increased glucose uptake (EC50 of 0.07 +/- 0.02 mu M) in differentiated skeletal muscle cells in presence of insulin. Furthermore, 7114863 was superior to rosiglitazone under similar experimental conditions without inducing PPAR-gamma agonist activity thus making it a very interesting scaffold. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.067
• 作为产物：
  描述：

  4-nitromethyl-2H-phthalazin-1-one 在 磷化氢 、 水 、 氢碘酸 作用下， 生成 4-氨甲基-1(2H)-酞嗪酮
  参考文献：
  名称：

  Mazkanowa; Wanag, Zhurnal Obshchei Khimii, 1958, vol. 28, p. 2798,2799;engl.Ausg.S.2822

  摘要：

  DOI：

文献信息

• [EN] TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN<br/>[FR] COMPOSES DE TRIAZOLO-PYRIDAZINE ET LEURS DERIVES, DESTINES AU TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
  申请人：MERCK & CO INC

  公开号：WO2005041971A1

  公开（公告）日：2005-05-12

  The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders - such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.

  本发明涉及一种在治疗神经病性疼痛中使用三唑吡啶化合物的方法。本发明还涉及在治疗精神和情绪障碍，如精神分裂症、焦虑、抑郁、躁郁症和恐慌，以及在治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍（如倒班引起的睡眠障碍和时差反应）、药物成瘾、药物滥用、药物戒断和其他疾病中使用三唑吡啶化合物的方法。本发明还涉及选择性结合到Ca通道α2δ-1亚基的新型三唑吡啶化合物。
• Imidazolophthalazine derivatives as ligands for gabaa receptors
  申请人：——

  公开号：US20040147517A1

  公开（公告）日：2004-07-29

  A class of substituted imidazolo[5,1-a]phthalazine derivatives as ligands for GABA A receptors which are partial or full inverse agonists of an &agr;5 receptor subunit while being relatively free of activity at &agr;1 and/or &agr;2 and/or &agr;3 receptor subunit binding sites; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of procon-vulsant activity.

  一类取代咪唑啉[5,1-a]萘嗪衍生物，作为GABAA受体的配体，它们是α5受体亚单位的部分或完全反向激动剂，同时在α1和/或α2和/或α3受体亚单位结合位点上相对缺乏活性；因此，它们对于增强认知有益，但可以减少或消除抗抗痉挛活性。
• Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
  申请人：——

  公开号：US20040034221A1

  公开（公告）日：2004-02-19

  Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  本文描述了包括某些喹啉羧酰胺和萘啶羧酰胺衍生物在内的Aza-和polyaza-萘啶基羧酰胺衍生物，作为HIV整合酶的抑制剂和HIV复制的抑制剂。这些化合物作为化合物或药物可接受的盐，或作为制药组合物中的成分，可用于预防或治疗HIV感染和治疗艾滋病，可选地与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。本文还描述了预防、治疗或延迟艾滋病发作的方法以及预防或治疗HIV感染的方法。
• Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain
  申请人：Lebsack D. Alec

  公开号：US20070213338A1

  公开（公告）日：2007-09-13

  The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α 2 δ-1 subunit of Ca channels.

  本发明涉及一种使用三唑并吡嗪化合物治疗神经病性疼痛的方法。本发明还涉及使用三唑并吡嗪化合物治疗精神和情绪障碍，例如精神分裂症、焦虑、抑郁、双相障碍和惊恐症，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍（例如倒班引起的睡眠障碍和时差反应）、药物成瘾、药物滥用、药物戒断和其他疾病的方法。本发明还涉及新型的三唑并吡嗪化合物，它们能够选择性地结合到Ca通道的α2δ-1亚基上。
• Spirohydantoin Aryl Cgrp Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090239870A1

  公开（公告）日：2009-09-24

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 and R 6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量A1，A2，A3，A4，A5，A6，A7，B，E1，E2，E3，E4，E5，G1，G2和R6如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的应用。